Cover Image
市場調查報告書

美國的經心肌血液循環重組術 (TMR) 設備市場

US Market Report for Transmyocardial Revascularization Devices 2018 - MedCore

出版商 iData Research Inc. 商品編碼 590197
出版日期 內容資訊 英文 390 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
美國的經心肌血液循環重組術 (TMR) 設備市場 US Market Report for Transmyocardial Revascularization Devices 2018 - MedCore
出版日期: 2017年11月01日 內容資訊: 英文 390 Pages
簡介

本報告提供美國的經心肌血液循環重組術 (TMR) 設備市場相關調查分析,疾病概要,產品的評估,市場分析等相關的系統性資訊。

摘要整理

美國的心血管手術和心臟瓣膜設備市場概要

競爭分析

市場趨勢

市場發展

治療數量

調查對象的醫療編碼

對象市場

主要的調查更新

版本履歷

第1章 調查手法

第2章 疾病概要

  • 基本結構

第3章 產品系列

  • 產品系列
  • FDA回收
  • 臨床實驗

第4章 經心肌血液循環重組術 (TMR) 設備市場

  • 簡介
  • 市場概要
  • 市場分析與預測
  • 促進因素及阻礙因素
    • 推動市場要素
    • 市場阻礙因素
  • 競爭市場佔有率分析

簡稱

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: iDATA_USCS18_MC_TR

Transmyocardial revascularization (TMR) is a surgically performed laser-based heart treatment procedure in which transmural channels are made in the heart muscle. Many scientific experts believe that these procedures encourage new vessel formation, also known as angiogenesis. TMR therapy is approved for patients suffering from chronic or severe angina. The American Heart Association (AHA) estimates that approximately 9.8 million Americans experience angina symptoms.

Angina is the medical term used for describing the chest pain or discomfort that an individual can experience when the heart does not receive an adequate supply of oxygen-rich blood. This can occur when the arteries supplying blood flow to the heart muscle become partially blocked or narrowed by the accumulation of fatty deposits known as plaque. This condition, where plaque progressively builds up in the interior walls of the arteries, resulting in reduced blood flow to the myocardium, ischemia and angina, is known as coronary atherosclerosis. The primary therapeutic options for treatment of coronary artery disease are drug therapy, percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG). However, many patients with severe angina experience inadequate response to pharmacological approaches and require surgical treatment such as PCI with or without stenting, or CABG. Many patients with chronic, severe angina are not candidates for PCI or CABG because of a variety of reasons including failed prior procedures, diffuse coronary artery disease, distal stenosis or extremely small coronary arteries. These patients represent the primary target population for treatment with TMR.

TABLE OF CONTENTS I

LIST OF FIGURES XII

LIST OF CHARTS XV

EXECUTIVE SUMMARY 1

U.S. CARDIAC SURGERY AND HEART VALVE DEVICE MARKET OVERVIEW 1

COMPETITIVE ANALYSIS 4

MARKET TRENDS 7

MARKET DEVELOPMENTS 11

PROCEDURE NUMBERS 12

PROCEDURE CODES INVESTIGATED 16

MARKETS INCLUDED 17

KEY REPORT UPDATES 19

VERSION HISTORY 20

RESEARCH METHODOLOGY 21

    • Step 1: Project Initiation & Team Selection 21
    • Step 2: Prepare Data Systems and Perform Secondary Research 24
    • Step 3: Preparation for Interviews & Questionnaire Design 26
    • Step 4: Performing Primary Research 27
    • Step 5: Research Analysis: Establishing Baseline Estimates 29
    • Step 6: Market Forecasts and Analysis 30
    • Step 7: Identify Strategic Opportunities 32
    • Step 8: Final Review and Market Release 33
    • Step 9: Customer Feedback and Market Monitoring 34

DISEASE OVERVIEW 35

  • 2.1 BASIC ANATOMY 35
    • 2.1.11 Coronary Artery Disease 37
    • 2.1.12 Myocardial Infarction 37
    • 2.1.13 Angina Pectoris 38
    • 2.1.14 Heart Valve Disease 39
    • 2.1.15 Congestive Heart Failure 39

PRODUCT PORTFOLIO 41

    • 3.1.1 Tissue Heart Valves 41
    • 3.1.2 Mechanical Tissue Heart Valves 43
    • 3.1.3 Annuloplasty Repair Devices 45
    • 3.1.4 Transcatheter Aortic Valve Replacement Devices 47
    • 3.1.5 Transcatheter Mitral Valve Repair Devices 49
    • 3.1.6 On-Pump Coronary Artery Bypass Devices 50
    • 3.1.7 Off-Pump Coronary Artery Bypass Devices 52
    • 3.1.8 Endoscopic Vessel Harvesting Devices 53
    • 3.1.9 Anastomosis Assist Devices 54
    • 3.1.10 Transmyocardial Revascularization Devices 55
    • 3.1.11 Ventricular Assist Devices 56
    • 3.1.12 Intra-Aortic Balloon Pump Device 57
    • 3.1.13 Temporary Artificial Heart Replacement Device 58
    • 3.1.14 Remote Hemodynamic Monitoring System Devices 59
    • 3.1.15 Patent Foramen Ovale Devices 59
    • 3.1.16 Atrial & Ventricular Septal Defect Device 61
    • 3.1.17 Left Atrial Appendage Closure Device 62
    • 3.1.18 Extracorporeal Membrane Oxygenation Machine 63
  • 3.2 FDA RECALLS 64
    • 3.2.1 MAQUET 64
    • 3.2.2 Medtronic 66
    • 3.2.3 HeartWare Inc 67
  • 3.3 CLINICAL TRIALS 68
    • 3.3.1 Medtronic 68
    • 3.3.2 St. Jude Medical 70
    • 3.3.3 Abiomed 75
    • 3.3.4 Heartware Inc 76

TRANSMYOCARDIAL REVASCULARIZATION DEVICE MARKET 78

  • 4.1 INTRODUCTION 78
  • 4.2 MARKET OVERVIEW 80
  • 4.3 MARKET ANALYSIS AND FORECAST 83
    • 4.3.1 Transmyocardial Revascularization Disposables Market 83
    • 4.3.2 Transmyocardial Revascularization Capital Equipment Market 85
      • 4.3.2.1 Transmyocardial Revascularization Laser Console Market 88
      • 4.3.2.2 Transmyocardial Revascularization Laser Console Service Market 90
  • 4.4 DRIVERS AND LIMITERS 92
    • 4.4.1 Market Drivers 92
    • 4.4.2 Market Limiters 93
  • 4.5 COMPETITIVE MARKET SHARE ANALYSIS 95

ABBREVIATIONS 98

APPENDIX: COMPANY PRESS RELEASES 101

LIST OF CHARTS

  • Chart 1 1: Cardiac Surgery and Heart Valve Devices Market by Segment, U.S., 2014 - 2024 3
  • Chart 1 2: Cardiac Surgery and Heart Valve Devices Market Overview, U.S., 2017 & 2024 3
  • Chart 4 1: Transmyocardial Revascularization Device Market by Segment, U.S., 2014 - 2024 81
  • Chart 4 2: Transmyocardial Revascularization Device Market Breakdown by Segment, U.S., 2017 82
  • Chart 4 3: Transmyocardial Revascularization Device Market Breakdown by Segment, U.S., 2024 82
  • Chart 4 4: Transmyocardial Revascularization Disposables Market, U.S., 2014 - 2024 84
  • Chart 4 5: Transmyocardial Revascularization Capital Equipment Market by Segment, U.S., 2014 - 2024 86
  • Chart 4 6: Transmyocardial Revascularization Capital Equipment Market Breakdown by Segment, U.S., 2017 87
  • Chart 4 7: Transmyocardial Revascularization Capital Equipment Market Breakdown by Segment, U.S., 2024 87
  • Chart 4 8: Transmyocardial Revascularization Laser Console Market, U.S., 2014 - 2024 89
  • Chart 4 9: Transmyocardial Revascularization Laser Console Service Market, U.S., 2014 - 2024 91
  • Chart 4 10: Leading Competitors, Transmyocardial Revascularization Device Market, U.S., 2017 97

LIST OF FIGURES

  • Figure 1 1: Cardiac Surgery and Heart Valve Devices Market Share Ranking by Segment, U.S., 2017 (1 of 4) 4
  • Figure 1 2: Cardiac Surgery and Heart Valve Devices Market Share Ranking by Segment, U.S., 2017 (2 of 4) 5
  • Figure 1 3: Cardiac Surgery and Heart Valve Devices Market Share Ranking by Segment, U.S., 2017 (3 of 4) 5
  • Figure 1 4: Cardiac Surgery and Heart Valve Devices Market Share Ranking by Segment, U.S., 2017 (4 of 4) 5
  • Figure 1 5: Companies Researched in this Report, U.S., 2017 6
  • Figure 1 6: Factors Impacting the Cardiac Surgery and Heart Valve Devices Market by Segment, U.S. (1 of 4) 7
  • Figure 1 7: Factors Impacting the Cardiac Surgery and Heart Valve Devices Market by Segment, U.S. (2 of 4) 8
  • Figure 1 8: Factors Impacting the Cardiac Surgery and Heart Valve Devices Market by Segment, U.S. (3 of 4) 9
  • Figure 1 9: Factors Impacting the Cardiac Surgery and Heart Valve Devices Market by Segment, U.S. (4 of 4) 10
  • Figure 1 10: Recent Events in the Cardiac Surgery and Heart Valve Devices Market, U.S., 2015 - 2017 11
  • Figure 1 11: Cardiac Surgery and Heart Valve Devices Procedures Covered, U.S., 2017 (1 of 4) 12
  • Figure 1 12: Cardiac Surgery and Heart Valve Devices Procedures Covered, U.S., 2017 (2 of 4) 13
  • Figure 1 13: Cardiac Surgery and Heart Valve Devices Procedures Covered, U.S., 2017 (3 of 4) 14
  • Figure 1 14: Cardiac Surgery and Heart Valve Devices Procedures Covered, U.S., 2017 (4 of 4) 15
  • Figure 1 15: Procedure Codes Investigated, U.S., 2017 16
  • Figure 1 16: Cardiac Surgery and Heart Valve Devices Markets Covered, U.S., 2017 (1 of 2) 17
  • Figure 1 17: Cardiac Surgery and Heart Valve Devices Markets Covered, U.S., 2017 (2 of 2) 18
  • Figure 1 18: Key Report Updates (1 of 2) 19
  • Figure 1 19: Key Report Updates (2 of 2) 20
  • Figure 1 20: Version History 20
  • Figure 3 1: Tissue Heart Valves by Company 42
  • Figure 3 2: Mechanical Tissue Heart Valves by Company 44
  • Figure 3 3: Annuloplasty Repair Devices by Company 46
  • Figure 3 4: Transcatheter Heart Valve Replacement Devices by Company 48
  • Figure 3 5: Transcatheter Mitral Valve Repair Devices by Company 49
  • Figure 3 6: On-Pump Coronary Artery Bypass Devices by Company 51
  • Figure 3 7: Off-Pump Coronary Artery Bypass Devices by Company 52
  • Figure 3 8: Endoscopic Vessel Harvesting Devices by Company 53
  • Figure 3 9: Anastomosis Assist Devices by Company 54
  • Figure 3 10: Transmyocardial Revascularization Devices by Company 55
  • Figure 3 11: Ventricular Assist Devices by Company 56
  • Figure 3 12: Intra-Aortic Balloon Devices by Company 57
  • Figure 3 13: Temporary Artificial Heart Replacement Devices by Company 58
  • Figure 3 14: Remote Hemodynamic Monitoring System Devices by Company 59
  • Figure 3 15: Patent Foramen Ovale Devices by Company 60
  • Figure 3 16: Atrial & Ventricular Septal Defect Devices by Company 61
  • Figure 3 17: Left Atrial Appendage Closure Devices by Company 62
  • Figure 3 18: Extracorporeal Membrane Oxygenation Machine by Company 63
  • Figure 3 19: Class 2 Device Recall MAQUET 64
  • Figure 3 20: Class 2 Device Recall MAQUET 64
  • Figure 3 21: Class 2 Device Recall MAQUET 65
  • Figure 3 22: Class 1 Device Recall Medtronic 66
  • Figure 3 23: Class 1 Device Recall Heartware Inc 67
  • Figure 3 24: The Medtronic Harmony™ Transcatheter Pulmonary Valve Clinical Study 68
  • Figure 3 25: Medtronic Transcatheter Aortic Valve Implant System (CoreValve System Family) Post Marketing Surveillance 68
  • Figure 3 26: Medtronic CoreValve Evolut R U.S. Clinical Study 69
  • Figure 3 27: Medtronic Transcatheter Aortic Valve Replacement in Low Risk Patients 69
  • Figure 3 28: AMPLATZER™ Post-infarct Muscular VSD Occluder Humanitarian Device Exemption 70
  • Figure 3 29: AMPLATZER Duct Occluder II Additional Sizes (ADO II AS) 70
  • Figure 3 30: HeartMate 3 CE Mark Study Long Term Follow-up (HM3 CE LTFU) 71
  • Figure 3 31: Trifecta™ GT Post Market Clinical Follow-up 71
  • Figure 3 32: AMPLATZER™ LAA Occluder Post Approval Study (PAS) 72
  • Figure 3 33: AMPLATZER™ Cardiac Plug Observational Post-Approval Study (ACP PAS China) 72
  • Figure 3 34: MOMENTUM 3 Continued Access Protocol (MOMENTUM 3 CAP) 73
  • Figure 3 35: AMPLATZER™ Amulet™ LAA Occluder Trial (Amulet IDE) 73
  • Figure 3 36: Prevention of Non-Surgical Bleeding by Management of HeartMate II 74
  • Figure 3 37: Door To Unloading With IMPELLA CP System in Acute Myocardial Infarction (DTU) 75
  • Figure 3 38: Protected PCI Study 75
  • Figure 3 39: Assessment of the WATCHMAN™ Device 76
  • Figure 3 40: Watchman FLX Left Atrial Appendage Closure Device Post Approval Study 76
  • Figure 3 41: Investigational Device Evaluation of the WATCHMAN FLX™ LAA Closure Technology 77
  • Figure 4 1: Transmyocardial Revascularization Device Market by Segment, U.S., 2014 - 2024 (US$M) 80
  • Figure 4 2: Transmyocardial Revascularization Disposables Market, U.S., 2014 - 2024 83
  • Figure 4 3: Transmyocardial Revascularization Capital Equipment Market by Segment, U.S., 2014 - 2024 (US$M) 85
  • Figure 4 4: Transmyocardial Revascularization Laser Console Market, U.S., 2014 - 2024 88
  • Figure 4 5: Transmyocardial Revascularization Laser Console Service Market, U.S., 2014 - 2024 90
  • Figure 4 6: Drivers and Limiters, Transmyocardial Revascularization Device Market, U.S., 2017 94
  • Figure 4 7: Leading Competitors, Transmyocardial Revascularization Device Market, U.S., 2017 96
  • Figure 6 1: Press Release Summary 101
Back to Top